Clinical Trial Update: Sandostatin for Patients With Androgen Independent Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Sandostatin (octreotide) in androgen-independent prostate cancer was terminated and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-12-11